newsfilter
← Earnings
Earnings Releases·

Kyntra Bio — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Total revenue from continuing operations for Q3 2026 was $1.8 million, an increase from $1.1 million in Q3 2025.
    • Net income from continuing operations for Q3 2026 was $0.2 million ($0.04 per share), compared to a net loss of $13.1 million ($3.25 per share) in Q3 2025.
    • Cash, cash equivalents, investments, and accounts receivable totaled $44.1 million as of September 30, 2026.
    • The company expects its cash position to fund operating plans into 2028.
    • For the nine months ended September 30, 2026, total revenue was $4.0 million compared to $5.2 million in the prior year period.
    • Net loss from continuing operations for the nine months ended September 30, 2026, was $3.0 million ($0.74 per share), compared to a net loss of $43.6 million ($10.79 per share) in the prior year period.
    • A gain on debt restructuring of $14.0 million was recorded for the nine months ended September 30, 2026.
    • Deferred revenue increased to $6.2 million (current) and $3.0 million (non-current) as of September 30, 2026, from $5.3 million (current) and $0.3 million (non-current) as of December 31, 2025.
    • Total liabilities decreased to $56.0 million as of September 30, 2026, from $115.1 million as of December 31, 2025.
    • Stockholders' deficit attributable to Kyntra Bio improved to $(29.2) million as of September 30, 2026, from $(30.0) million as of December 31, 2025.
  • Guidance and Future Outlook:

    • Initiation of the pivotal Phase 3 trial for roxadustat in LR-MDS patients with high transfusion burden is planned for Q1 2027, subject to securing a strategic partnership or external capital raise.
    • The company expects to save over $20 million in operating expenses in 2027 and 2028 following the discontinuation of FG-3246 and FG-3180.
    • The amended royalty financing agreement will terminate once the remaining $15 million cap is reached, allowing Kyntra Bio to retain all subsequent EVRENZO royalties in Astellas territories.
  • Business Segments and Product Lines:

    • Roxadustat: The company is a pure-play rare disease entity focused on roxadustat for anemia associated with lower-risk myelodysplastic syndromes (LR-MDS).
    • FG-3246 and FG-3180: Development of these programs was discontinued following a pre-specified interim analysis in metastatic castration-resistant prostate cancer (mCRPC) that showed insufficient efficacy. Enrollment in the FG-3246 Phase 2 study was closed.
    • Royalty Financing: In August 2026, the company amended its royalty financing agreement with NQ Project Phoebus, L.P., reducing the maximum aggregate payment obligation from $125 million to $65 million.
    • Astellas Collaboration: Remaining royalty payments are capped at $15 million, derived from 50% of roxadustat drug product revenue recognized from Astellas in territories excluding Japan.
  • Market and Competitive Landscape:

    • Roxadustat is approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients.
    • Kyntra Bio holds sole rights to roxadustat in the United States, Canada, Mexico, and markets not held by AstraZeneca or licensed to Astellas.
    • Astellas and Kyntra Bio collaborate on commercialization in Japan, Europe, Turkey, Russia, CIS, the Middle East, and South Africa.
    • The company identifies a multi-billion-dollar commercial opportunity in the LR-MDS market driven by significant unmet medical need.
  • Risks and Challenges:

    • The Phase 3 trial initiation is contingent upon the execution of a strategic partnership or an external capital raise.
    • Clinical trial results, including enrollment and efficacy, remain subject to uncertainty.
    • Forward-looking statements regarding cash sufficiency, product success, and regulatory interactions are subject to risks and uncertainties described in the company's SEC filings.
  • Management Commentary and Tone:

    • CEO Thane Wettig stated the company is completing its transformation to a "pure-play, rare disease company laser-focused" on the Phase 3 roxadustat trial.
    • Management characterized the decision to discontinue FG-3246 as following a "pre-planned interim analysis showing insufficient efficacy."
    • The tone reflects a strategic pivot to focus resources on the LR-MDS opportunity while managing financial obligations through debt restructuring.
  • Other Key Points:

    • Andrew E. Singer, MBA, was appointed to the Board of Directors.
    • The amended royalty agreement includes an accelerated upfront payment of $42.6 million to NQ Project Phoebus, L.P., bringing total payments made to date to $50 million, representing a full return of the investor's capital.
    • The company hosted a conference call and webcast presentation on November 16, 2026, to discuss results and business updates.
Company
KYNTRA BIO INC
Sector
Healthcare
Industry
Biotechnology